Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19858386 | 1.00 | NOS1 (0.45) | NOS1NOS3NOS2LMNAKMT2A | |
| SCHEMBL31606685 | 1.00 | NOS1 (0.45) | NOS1NOS3NOS2LMNAKMT2A | |
| SCHEMBL9952902 | 1.00 | NOS1 (0.45) | NOS1NOS3NOS2LMNAKMT2A | |
| SCHEMBL28179952 | 1.00 | NOS1 (0.45) | NOS1NOS3NOS2LMNAKMT2A | |
| SCHEMBL27183262 | 1.00 | NOS1 (0.45) | NOS1NOS3NOS2LMNAKMT2A | |
| SCHEMBL304098 | 1.00 | NOS1 (0.45) | NOS1NOS3NOS2LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL19858050 | 0.98 | NOS1 (0.44) | NOS1NOS3NOS2LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL2409207 | 0.98 | NOS1 (0.44) | NOS1NOS3NOS2LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL1825341 | 0.98 | NOS1 (0.44) | NOS1NOS3NOS2LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL1825344 | 0.98 | NOS1 (0.44) | NOS1NOS3NOS2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239879-A | Method for preparing 3-substituted oxindole, dihydroisoindigo and tetra-substituted ethane based on primary amine and application of primary amine | 泰山学院 | 2024-06-25 | — | — | CN | claimed |
| CN-110790674-A | Method for continuously producing O-tert-butyl-L-threonine tert-butyl ester | 熊飞龙 | 2020-02-14 | — | — | CN | claimed |
| CN-109134314-A | A kind of preparation method of polypeptide raw material N- fluorenylmethoxycarb-nyl -nyl O-tert-butyl threonine | 吉尔生化（上海）有限公司 | 2019-01-04 | — | — | CN | claimed |
| CN-106414435-A | Amino-substituted isothiazoles | 拜耳制药股份公司 | 2017-02-15 | — | — | CN | claimed |
| CN-1026979-C | One-step synthesis of tert-butyl threonine | UNIV JILIN (CN) | 1994-12-14 | — | — | CN | claimed |
| CN-1041757-A | The single stage method of tert-butyl threonine is synthetic | UNIV JILIN (CN) | 1990-05-02 | — | — | CN | claimed |
| US-4401757-A | CONVERTING ANIMAL INSULIN TO DES-B30-INSULIN, REACTING WITH THREONINE | SHIONOGI & CO., LTD. (JP) | 1983-08-30 | — | — | US | claimed |
| US-4400465-A | FROM ANIMAL INSULIN BY EXCHANGING THE B30 ALANINE WITH THREONINE | SHIONOGI & CO., LTD. (JP) | 1983-08-23 | — | — | US | claimed |
| EP-0017938-B1 | PROCESS FOR PREPARING A B30-THREONINE INSULIN | SHIONOGI & CO., LTD. (JP) | 1983-08-03 | — | — | EP | claimed |
| US-4320196-A | ENZYMATIC CATALYZED REACTION WITH THREONINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 1982-03-16 | — | — | US | claimed |
| US-4320197-A | THREONINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 1982-03-16 | — | — | US | claimed |
| EP-0017938-A1 | Process for preparing a B30-threonine insulin | SHIONOGI & CO., LTD. (JP) | 1980-10-29 | — | — | EP | claimed |
| US-20260103498-A1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2026-04-16 | — | — | US | disclosed |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCE INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| CN-120136962-A | Fibroblast activation protein targeting compound, nuclide marker thereof, pharmaceutical composition containing same and application | 潍坊市人民医院(潍坊市公共卫生临床中心、潍坊市职业病医院) | 2025-06-13 | — | — | CN | disclosed |
| EP-0056951-A1 | Process for the preparation of human insulin or its derivatives from pig insulin or its derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-08-04 | — | — | EP | disclosed |
| US-4320197-A | THREONINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 1982-03-16 | — | — | US | disclosed |
| US-4320196-A | ENZYMATIC CATALYZED REACTION WITH THREONINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 1982-03-16 | — | — | US | disclosed |
| EP-0017938-A1 | Process for preparing a B30-threonine insulin | SHIONOGI & CO., LTD. (JP) | 1980-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103498-A1 | METHOD FOR PREPARING LIRAGLUTIDE | GLP1R, IAPP, VIP | NOS1 828/4885NOS3 1174/4885NOS2 2202/4885 |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | NOS1 2449/4885NOS3 1219/4885NOS2 1844/4885 |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CCR10, CCR1, CCR3 | NOS1 1238/4885NOS3 539/4885NOS2 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.